The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1455
ISSUE1455
November 10, 2014
A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C
November 10, 2014 (Issue: 1455)
The FDA has approved a fixed-dose combination (Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.